在口腔癌中共同准EGFR和螺旋组装检查点途径的治疗影响的探索
Mafalda Calheiros-Lobo1, João P N Silva1, Bárbara Pinto1
1UNIPRO-Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Rua Central de Gandra, 1317, 4585-116 Gandra, Portugal.
Pharmaceutics
|September 28, 2024
概括
头部和部癌症 (HNCs) 正在增加,口腔状细胞癌 (OSCC) 是常见的. 准表皮生长因子受体 (EGFR) 和单极1 (MPS1) 显示出新的HNC治疗的希望.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 分子治疗学分子治疗学
背景情况:
- 全球头癌 (HNC) 发病率正在上升,口腔状细胞癌 (OSCC) 是最常见的亚型.
- 由于形和功能障碍 (吞,说话),OSCC显著影响生活质量,特别是在老年男性中.
- 目前的治疗方法 (手术,放射治疗,化疗) 在晚期治疗效果有限,需要新的治疗策略.
研究的目的:
- 审查表皮生长因子受体 (EGFR) 和单极1 (MPS1) 作为HNC的关键治疗点.
- 分析EGFR和MPS1的分子机制及其抑制对癌细胞的影响.
- 探索组合疗法的潜力,包括微管向剂 (MTA),以改善HNC治疗结果.
主要方法:
- 文献综述侧重于EGFR和MPS1在HNC中的分子机制.
- 分析现有的治疗策略及其局限性.
- 探索针对性疗法和组合方法的临床前和临床数据.
主要成果:
- 皮表皮生长因子受体 (EGFR) 在80-90%的HNC中过度表达,但基于 cetuximab的疗法表现出有限的成功.
- 单极旋1 (MPS1) 在线分裂过程中对基因组稳定性至关重要,在各种癌症中过度表达,呈现出一个可行的治疗标.
- 抑制EGFR和MPS1,特别是与MTA等药物结合使用时,显示出增强抗癌效应的潜力.
结论:
- EGFR和MPS1为新型HNC疗法提供了有希望的分子标.
- 针对这些途径,特别是通过组合方法,可以克服当前的治疗局限性并改善患者的生存率.
- 对MPS1抑制剂和组合策略的进一步研究是有必要的,以推进HNC治疗范式.
更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.0K
12:03Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma
Published on: July 25, 2011
19.2K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:15M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K